title: FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls.
abstract: BACKGROUND
  Fibroblast growth factor receptor 4 (FGFR4) displays multiple biological activities, including mitogenic and angiogenic activity, and plays important roles in the etiology and progression of prostate cancer. Gly388Arg polymorphism in FGFR4 gene has been reported to be involved in prostate cancer incidence and aggressiveness in several studies. To derive a more precise estimation of the relationship, a meta-analysis was performed.
  
  
  METHODS
  Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association.
  
  
  RESULTS
  The Arg388 allele increased prostate cancer risk compared with Gly388 allele (OR = 1.17, 95% CI = 1.07-1.29). When stratified by race, there was a significantly increased prostate cancer risk in Asian and Caucasian populations. Moreover, prostate cancer patients with Arg/Arg genotype had a 1.34-fold increased risk of advanced prostate cancer (95% CI: 1.03-1.74) compared with those with Gly/Gly+Gly/Arg genotype.
  
  
  CONCLUSIONS
  This meta-analysis showed the evidence that FGFR4 Gly388Arg polymorphism was associated with an increased risk of prostate cancer development and progression, suggesting that FGFR4 Gly388Arg polymorphism could be a marker for prostate cancer development and progression.
authors.affiliation: Department of Urology, The Affiliated ZhongDa Hospital of Southeast University, 87 Dingjia Bridge Hunan Road, Nanjing, 210009, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Xu
authors.forename: Na
authors.initials: N
authors.lastname: Tong
authors.forename: Shu Q
authors.initials: SQ
authors.lastname: Chen
authors.forename: Li X
authors.initials: LX
authors.lastname: Hua
authors.forename: Zeng J
authors.initials: ZJ
authors.lastname: Wang
authors.forename: Zheng D
authors.initials: ZD
authors.lastname: Zhang
authors.forename: Ming
authors.initials: M
authors.lastname: Chen
mesh_terms: D019943:Amino Acid Substitution / Q000235:genetics / Q000502:physiology; D001120:Arginine / Q000235:genetics; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D002277:Carcinoma / Q000235:genetics* / Q000473:pathology*; D016022:Case-Control Studies; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000473:pathology; D018450:Disease Progression; D005998:Glycine / Q000235:genetics; D006801:Humans; D008297:Male; D020641:Polymorphism, Single Nucleotide / Q000502:physiology; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology*; D051499:Receptor, Fibroblast Growth Factor, Type 4 / Q000235:genetics* / Q000502:physiology
chemical_list: D014408:Biomarkers, Tumor; D001120:Arginine; C496371:FGFR4 protein, human; D051499:Receptor, Fibroblast Growth Factor, Type 4; D005998:Glycine